GAINESVILLE, Fla., July 20, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that an article discussing advantages of NIMBUS antimicrobial technology has been published in the June 2011 issue of Wound Practice and Research, a prominent Australian wound care journal. The article is titled "Caution: When Combining Topical Wound Treatments, More Is Not Always Better" and describes important and potentially damaging interactions that can occur between some commonly used wound treatments. As explained by the senior author, Gregory Schultz, PhD, University of Florida Research Foundation Professor, "wound care clinicians need to understand that some combinations of wound dressings and treatments can destructively interact, reducing their effectiveness, while other combinations are potentially helpful."
According to the article, BIOGUARD wound dressing is compatible with Santyl®, a frequently used collagenase debriding agent, whereas many other dressings deactivate Santyl's active ingredient. Dressings that were found to have 50% to >90% inhibitory effect on the Santyl active include those containing silver, iodine, and PHMB (polyhexamethylene biguanide). BIOGUARD can also be used with Dakin's Solution®, a popular wound cleanser based on hypochlorite, while dressings with PHMB such as Kerlix® AMD should not be used because hypochlorite deactivates the active antimicrobial agent in the dressing.
"BIOGUARD dressings with NIMBUS antimicrobial technology offer superior versatility and have been designed to allow worry-free use in the increasingly complex wound care environment," said Albina Mikhaylova, PhD, a co-author and Senior Scientist at Quick-Med Technologies. She explained, "NIMBUS is an important antimicrobial technology for medical devices because it doesn't leach or suffer depletion, doesn't initiate bacterial resistance, doesn't interfere with tissue healing, and prevents odor generation. The article reports that BIOGUARD can be safely combined with other important wound treatments."
BIOGUARD® bacterial barrier wound dressings are marketed under license from Quick-Med by Derma Sciences, Inc. (Nasdaq:DSCI) and Medline Industries, Inc.
A copy of the article is available on Quick-Med's website at: http://content.stockpr.com/qmdt/media/105d792c3b390a1196352dd5586087e0.pdf
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo clearance from the U.S. Food and Drug Administration and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. All other trademarks are property of their respective owners.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies, Inc. J. Ladd Greeno, CEO (888) 835.2211 Ext 102 email@example.com Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 firstname.lastname@example.org